Market cap
$467 Mln
Revenue (TTM)
$275 Mln
P/E Ratio
--
P/B Ratio
25.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 14.07 | 71.14 | 86.75 | -- | -- |
| EBIT | 91.73 | 98.52 | 89.24 | 22.57 | 13.21 |
| Net Profit | 20.96 | 53.63 | 69.77 | 15.26 | 8.26 |
| EPS | 22.03 | 59.91 | 72.98 | 20.07 | 12.12 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -7,989.16 | -7,989.16 | -8.00 | -87.45 | -474.76 |
| Net Margin
| -- | 7,140.60 | -30.19 | -- | -- |
| Return on equity
| 180.69 | 3,062.33 | -- | 63.97 | 204.89 |
| Return on Capital
| -1,625.26 | -1,031.88 | -- | 159.15 | -4,579.49 |
| Return on Assets
| -74.50 | -78.90 | -19.45 | -69.41 | -84.41 |
| Debt to Equity (x)
| -- | -- | -0.48 | -0.48 | -0.80 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
159.15
|
-4,579.49
|
-455.44
|
-212.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
63.97
|
204.89
|
273.21
|
14,877.58
|
|
Peer Median
|
-39.52
|
--
|
--
|
--
|
--
|
ROA
-19.45
Higher than Peers by 11.37
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-19.45
|
-69.41
|
-84.41
|
-69.68
|
-111.63
|
|
Peer Median
|
-30.82
|
--
|
--
|
--
|
--
|
EBIT Margin
-8.00
Higher than Peers by 71.54
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-8.00
|
-87.45
|
-474.76
|
-23,405.28
|
--
|
|
Peer Median
|
-79.54
|
--
|
--
|
--
|
--
|
Net Margin
-30.19
Higher than Peers by 58.55
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-30.19
|
-126.35
|
-605.09
|
-29,558.94
|
--
|
|
Peer Median
|
-88.75
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
86.75
Higher than Peers by 30.38
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
86.75
|
2.17
|
80.01
|
--
|
--
|
|
Peer Median
|
56.37
|
--
|
--
|
--
|
--
|
EBIT Growth
89.24
Higher than Peers by 90.22
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
89.24
|
41.62
|
-64.33
|
6.33
|
-24.31
|
|
Peer Median
|
-0.98
|
--
|
--
|
--
|
--
|
Net Profit Growth
69.77
Higher than Peers by 75.76
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
69.77
|
33.82
|
-65.84
|
-1.96
|
-37.42
|
|
Peer Median
|
-5.99
|
--
|
--
|
--
|
--
|
EPS Growth
72.98
Higher than Peers by 58.89
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
72.98
|
0.36
|
-0.20
|
0.18
|
-0.26
|
|
Peer Median
|
14.09
|
--
|
--
|
--
|
--
|
Book Value Growth
28.87
Higher than Peers by 37.60
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
28.87
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-8.73
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.48
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-0.48
|
-0.48
|
-0.80
|
-1.91
|
-1.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
0.00
|
0.00
|
0.00
|
-0.01
|
-0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.76
Lower than Peers by 4.15
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
1.76
|
1.73
|
4.20
|
10.25
|
6.12
|
|
Peer Median
|
5.91
|
--
|
--
|
--
|
--
|
Quick Ratio
1.72
Lower than Peers by 4.07
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
1.72
|
1.69
|
4.16
|
10.22
|
6.12
|
|
Peer Median
|
5.79
|
--
|
--
|
--
|
--
|
Interest Coverage
-0.32
Higher than Peers by 2.09
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-0.32
|
-2.25
|
-3.64
|
-3.80
|
-6.24
|
|
Peer Median
|
-2.41
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
39.14
Higher than Peers by 20.11
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
39.14
|
44.62
|
70.22
|
240.03
|
--
|
|
Peer Median
|
19.03
|
--
|
--
|
--
|
--
|
Asset Turnover
0.64
Higher than Peers by 0.58
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
0.64
|
0.55
|
0.14
|
0.00
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
121.94
|
133.65
|
438.35
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
70.52
|
101.15
|
1,321.02
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
125.18
|
529.30
|
24,712.33
|
4,461.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
67.28
|
-294.50
|
-22,952.96
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
-5.54
|
-1.73
|
-2.32
|
-2.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
25.37
Higher than Peers by 20.93
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
25.37
|
-2.79
|
-2.27
|
-6.44
|
-6.20
|
|
Peer Median
|
4.44
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-2.20
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
-2.20
|
-8.57
|
-1.84
|
-1.42
|
-2.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
467
Higher than Peers by 308
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Phathom Pharmaceuticals (PHAT)
|
467
|
--
|
--
|
--
|
--
|
|
Peer Median
|
159
|
--
|
--
|
--
|
--
|